Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

VERIFY: A Comprehensive Approach to Understanding and Ending Youth E-cigarette Addiction

Led by Peter Mohler, the vice dean for research and director of the Davis Heart & Lung Research Institute at the Ohio State College of Medicine and Wexner Medical Center. This team comprised of investigators in the Colleges of Medicine, Nursing, Public Health and Engineering and the Comprehensive Cancer Center will work to provide answers about the short- and long-term health effects of e-cigarettes, including their impact on the brain, lungs, and heart; the most effective regulations to reduce the appeal and addictiveness of e-cigarettes for youth; and the best methods to help youth addicted to e-cigarettes quit.

Team VERIFY: Vaping’s End through Research and Innovation For Youth will recruit youth for a year-long study to look at the relationship between nicotine form, concentration and flavorings on youth e-cig use, addiction, neurocognitive outcomes and pulmonary health compared to healthy peers.

They will also study the influence of nicotine form, concentration and flavor on youth puffing behavior, nicotine delivery, abuse liability, toxicant exposure and acute cardiovascular and pulmonary effects; and they will develop and test a multi-point, scalable vaping cessation program to include quit-line-delivered phone counseling, text-based cessation, nicotine replacement therapy and online cessation support.

YOU MAY BE INTERESTED IN

A year ago, when he was sworn in as director of the National Cancer Institute, Anthony G. Letai set a goal: Reassure cancer researchers that the institute will keep a steady course aimed at finding treatments for cancer.
Michael R. Caputo, a cancer survivor and a Republican political operative with a wide-ranging resume, was named to the President’s Cancer Panel, a board formed under the National Cancer Act to monitor the National Cancer Program and report to the president about “barriers to progress in reducing the burden of cancer.”
For over two decades, the ASCO Genitourinary Cancers Symposiumhas stood as the premier global event that has helped advance cancer science and transform care. The 2027 Symposium will continue this legacy from Feb. 11–13 in San Francisco by bringing together the largest international audience in GU oncology to help define tomorrow’s standards of care. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login